MBIO
MUSTANG BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.37
−0.90%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.37
From 52W high−76.24%
Volume9099.00
Market cap$2.83M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.37
From 52W high
−76.24%
Volume
9099.00
Market cap
$2.83M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.1x
P/E (TTM)
—
RSI (14)
28.9
MomentumView details →
1D Return
−0.90%
YTD Return
−61.26%
SummaryUpdated Jun 1, 2026
Mustang Bio, Inc. (NASDAQ:MBIO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, Massachusetts. The company went public in August 2017 and focuses on developing cutting-edge cell and gene therapies designed to treat hematologic cancers, solid tumors, and rare genetic diseases. Mustang Bio operates in the highly specialized biotechnology sector, working to translate breakthrough medical research into potential cures for patients with limited treatment options.
Similar companies
Latest newsMore news →
No recent news for MBIO.